Argent BioPharma (ASX:RGT) and AusCann Group Holdings signed a strategic heads of agreement to advance cannabinoid-based pharmaceutical development through the exchange of proprietary datasets and regulatory expertise, according to a Tuesday Australian bourse filing.
AusCann will license Argent BioPharma's CannEpil CMC and Dossier specifically for non-epilepsy-related pharmaceutical programs.
The companies will also gain access to AusCann's proprietary self-emulsifying hard-shell capsule formulation, Neuvis, including access to pharmacokinetic and pharmacodynamic data.
The firms will also establish a joint steering committee to coordinate research and development efforts as well as optimize regulatory strategies.
The agreement also includes a deferred licensing fee structure, with royalties on pharmaceutical products developed using jointly leveraged data, research and development, or assets.
Financial terms were not disclosed.
Argent BioPharma's shares were down almost 3% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。